Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP)
by Zacks Equity Research
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tricida (TCDA) Plummets on Regulatory Update on Veverimer
by Zacks Equity Research
Tricida (TCDA) tanks on FDA notification about the identification of deficiencies in its ongoing review of the NDA for pipeline candidate, veverimer (TRC101).
Celsion Down on DMC Recommendation to Stop Liver Cancer Study
by Zacks Equity Research
Celsion (CLSN) plummets on DMC recommendation to stop its phase III study assessing the efficacy of ThermoDox for HCC.
Horizon Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Horizon Therapeutics Public.
Is Horizon Therapeutics (HZNP) Stock a Solid Choice Right Now?
by Zacks Equity Research
Horizon Therapeutics (HZNP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Is Horizon Therapeutics (HZNP) Up 13.2% Since Last Earnings Report?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) beat on earnings and sales in the first quarter of 2020. The company lifts net sales guidance for the full year.
Horizon Therapeutics (HZNP) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 91.30% and 25.28%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Hanger (HNGR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Hanger's (HNGR) first-quarter 2020 results are likely to reflect strong performance at its Patient Care segment, partially offset by high costs.
Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Horizon Therapeutics (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Horizon Therapeutics (HZNP) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Horizon Therapeutics (HZNP) Down 16.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Horizon Therapeutics' (HZNP) Q4 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) beat earnings and sales estimates in the fourth quarter of 2019.
Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 30.23% and 3.31%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates
by Zacks Equity Research
It was a low-key week for the biotech sector with updates from just a few small biotech companies.
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter, which is partially offset by lower royalties from Relvar/Breo Ellipta.
Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP)
by Zacks Equity Research
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
REGN vs. HZNP: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. HZNP: Which Stock Is the Better Value Option?
Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza
by Zacks Equity Research
Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon
by Zacks Equity Research
A low-key week for the biotech sector with a few pipeline and regulatory updates.
Horizon Therapeutics' Stock Up in a Year on Pipeline Progress
by Zacks Equity Research
Horizon Therapeutics' (HZNP) shares have risen in the past year owing to the development of its pipeline candidates.
ALXN vs. HZNP: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. HZNP: Which Stock Is the Better Value Option?